Financial Performance - For the fiscal year ending December 31, 2025, the group's revenue decreased by approximately 2.7% to about HKD 161.8 million, compared to HKD 166.2 million in the fiscal year 2024[5] - The group's gross profit for the fiscal year 2025 decreased by approximately 53.8% to about HKD 26.5 million, down from HKD 57.4 million in the fiscal year 2024[5] - The group's net loss after tax for the fiscal year 2025 decreased by approximately 52.9% to about HKD 16.4 million, compared to HKD 34.8 million in the fiscal year 2024[5] - The basic and diluted loss per share attributable to the owners of the company for the fiscal year 2025 was HKD 0.0282, compared to HKD 0.0415 in the fiscal year 2024[6] - The company reported a pre-tax loss of HKD 34,690,000 due to significant impairment losses on loans and receivables, compared to a gain of HKD 4,003,000 in 2024[36] - The net loss attributable to the company owners for fiscal year 2025 was approximately HKD 16.4 million, a significant improvement of 52.7% compared to approximately HKD 34.7 million in fiscal year 2024[62] Assets and Liabilities - The total current assets decreased to HKD 470.7 million in 2025 from HKD 493.8 million in 2024, with a notable decrease in cash and cash equivalents from HKD 47.8 million to HKD 24.3 million[10] - The total current liabilities decreased significantly to HKD 71.4 million in 2025 from HKD 121.7 million in 2024, indicating improved liquidity management[10] - The total assets of the company as of December 31, 2025, were HKD 499,909,000, a decrease from HKD 525,631,000 in 2024[34] - The company’s total liabilities increased to HKD 125,492,000 in 2025 from HKD 74,915,000 in 2024, reflecting a rise of 67.2%[34] - As of December 31, 2025, the company recorded net current assets of approximately HKD 399.3 million, an increase from HKD 372.0 million as of December 31, 2024[86] Revenue Segmentation - For the year ending December 31, 2025, total revenue from external customers was HKD 161,762,000, with contributions of HKD 138,744,000 from longevity science and HKD 23,018,000 from lending and financial consulting[25] - The longevity science business segment reported revenue of approximately HKD 138.7 million for the fiscal year 2025, a decrease from HKD 142 million in fiscal year 2024[79] - The financial performance of the lending and financial consulting division recorded revenue of approximately HKD 23,000,000 for the fiscal year 2025, a decrease from HKD 24,200,000 in the fiscal year 2024[68] Investments and Acquisitions - The company acquired Asia Comprehensive Cell Bank Limited to enhance its capabilities in cell and gene therapy, aiming to create a comprehensive service platform for longevity science[52] - The company has agreed to acquire 25% of the issued share capital of Asia Integrated Cell Bank Limited for an initial consideration of HKD 300,000,000, which will be paid through the issuance of non-redeemable convertible bonds[109] Operational Developments - The company is developing a digital system for patient management and service processes, expected to be operational in Q2 2026, enhancing efficiency in health management[53] - The group plans to establish a Longevity Medical Transformation Center in Asia to implement leading cell and gene therapies, enhancing human health[58] - The group aims to expand its market presence by establishing Longevity Medical Centers in Singapore and Malaysia as part of its global strategy[58] Legal and Compliance - The company is involved in a legal dispute with Yuhe Holdings Limited, claiming a total principal amount of HKD 220,000,000 for convertible bonds, which could convert into 110,000,000 shares of the company[107] - The audit committee has reviewed and approved the consolidated financial statements for the fiscal year 2025, ensuring compliance with applicable accounting standards and regulations[119] - The company has confirmed compliance with risk management and internal control guidelines, with processes in place for identifying and addressing significant risks[115] Shareholder Information - The group did not recommend the payment of a final dividend for the fiscal year 2025, consistent with the previous fiscal year[5] - The board of directors has not recommended any dividend for the fiscal year 2025, consistent with the previous fiscal year[111] - The total number of issued ordinary shares increased to 636,654,300 shares as of December 31, 2025, compared to 546,529,549 shares as of December 31, 2024[87] Employee and Operational Efficiency - The group’s professional team comprised approximately 43 employees as of December 31, 2025[58] - The group has issued a total of 636,654,300 ordinary shares as of December 31, 2025, with an additional 90,124,751 shares issued during the fiscal year 2025[100] - The company has adhered to the corporate governance code, with some deviations noted, particularly regarding the roles of the Chairman and CEO being held by the same individual[113]
中基长寿科学(00767) - 2025 - 年度业绩